TY - JOUR
T1 - The HIV/HCV-Coinfected Patient and New Treatment Options
AU - Vachon, Marie Louise C.
AU - Dieterich, Douglas T.
PY - 2011/8
Y1 - 2011/8
N2 - Hepatitis C (HCV) treatment is on the cusp of change with the approval of the first direct-acting antivirals: telaprevir and boceprevir. Drug-drug interactions with HIV antiretrovirals, increased toxicity, and rapid selection of HCV-resistant mutants are among the treatment complexities expected in this difficult-to-treat population. Until the current standard of care changes, focus should be on strategies to optimize management of HIV/HCV-coinfected patients with currently available options. This article reviews the latest predictive factors of response to HCV treatment with the current standard of care in HIV-coinfected patients, and new treatment options.
AB - Hepatitis C (HCV) treatment is on the cusp of change with the approval of the first direct-acting antivirals: telaprevir and boceprevir. Drug-drug interactions with HIV antiretrovirals, increased toxicity, and rapid selection of HCV-resistant mutants are among the treatment complexities expected in this difficult-to-treat population. Until the current standard of care changes, focus should be on strategies to optimize management of HIV/HCV-coinfected patients with currently available options. This article reviews the latest predictive factors of response to HCV treatment with the current standard of care in HIV-coinfected patients, and new treatment options.
KW - Coinfection
KW - Direct-acting antivirals
KW - HIV
KW - Hepatitis C
KW - Treatment
UR - https://www.scopus.com/pages/publications/80051939478
U2 - 10.1016/j.cld.2011.05.006
DO - 10.1016/j.cld.2011.05.006
M3 - Review article
C2 - 21867938
AN - SCOPUS:80051939478
SN - 1089-3261
VL - 15
SP - 585
EP - 596
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
IS - 3
ER -